SCOPUS 정보 검색 플랫폼

Nature Reviews Drug Discovery

Volumn 10, Issue 5, 2011, Pages 335-336

Belimumab

(3) Sanz, Iñaki a Yasothan, Uma b Kirkpatrick, Peter c

a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY (United States)

b IQVIA (United States)

c Nature Reviews Drug Discovery ^* (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; B CELL ACTIVATING FACTOR; BELIMUMAB; CORTISONE ACETATE PLUS NEOMYCIN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB;

DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; B-CELL ACTIVATING FACTOR; DRUG APPROVAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955637390 PISSN: 14741776 EISSN: 14741784 Source Type: Journal
DOI: 10.1038/nrd3436 Document Type: Short Survey

Times cited : (37)

References (10)

1
- 77956289643
- Biological therapy for lupus nephritis - Tribulations and trials
- Smith, R. M. et al. Biological therapy for lupus nephritis - tribulations and trials. Nature Rev. Rheumatol. 6, 547-552 (2010).
- (2010) Nature Rev. Rheumatol. , vol.6 , pp. 547-552
- Smith, R.M.¹

2
- 77953182426
- B cells as therapeutic targets in SLE
- Sanz, I. & Lee, F. E. B cells as therapeutic targets in SLE. Nature Rev. Rheumatol. 6, 326-337 (2010).
- (2010) Nature Rev. Rheumatol. , vol.6 , pp. 326-337
- Sanz, I.¹ Lee, F.E.²

3
- 0033538468
- BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator
- DOI 10.1126/science.285.5425.260
- Moore, P. A. et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285, 260-263 (1999). (Pubitemid 29330000)
- (1999) Science , vol.285 , Issue.5425 , pp. 260-263
- Moore, P.A.¹ Belvedere, O.² Orr, A.³ Pieri, K.⁴ LaFleur, D.W.⁵ Feng, P.⁶ Soppet, D.⁷ Charters, M.⁸ Gentz, R.⁹ Parmelee, D.¹⁰ Li, Y.¹¹ Galperina, O.¹² Giri, J.¹³ Roschke, V.¹⁴ Nardelli, B.¹⁵ Carrell, J.¹⁶ Sosnovtseva, S.¹⁷ Greenfield, W.¹⁸ Ruben, S.M.¹⁹ Olsen, H.S.²⁰ Fikes, J.²¹ Hilbert, D.M.²² more..

4
- 0035167632
- Cutting edge: A role for B lymphocyte stimulator in systemic lupus erythematosus
- Zhang J. et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J. Immunol.166, 6-10 (2001). (Pubitemid 32038409)
- (2001) Journal of Immunology , vol.166 , Issue.1 , pp. 6-10
- Zhang, J.¹ Roschke, V.² Baker, K.P.³ Wang, Z.⁴ Alarcon, G.S.⁵ Fessler, B.J.⁶ Bastian, H.⁷ Kimberly, R.P.⁸ Zhou, T.⁹

5
- 0242495115
- Generation and Characterization of LymphoStat-B, a Human Monoclonal Antibody That Antagonizes the Bioactivities of B Lymphocyte Stimulator
- DOI 10.1002/art.11299
- Baker K. P. et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 48, 3253-3265 (2003). (Pubitemid 37409340)
- (2003) Arthritis and Rheumatism , vol.48 , Issue.11 , pp. 3253-3265
- Baker, K.P.¹ Edwards, B.M.² Main, S.H.³ Choi, G.H.⁴ Wager, R.E.⁵ Halpern, W.G.⁶ Lappin, P.B.⁷ Riccobene, T.⁸ Abramian, D.⁹ Sekut, L.¹⁰ Sturm, B.¹¹ Poortman, C.¹² Minter, R.R.¹³ Dobson, C.L.¹⁴ Williams, E.¹⁵ Carmen, S.¹⁶ Smith, R.¹⁷ Roschke, V.¹⁸ Hilbert, D.M.¹⁹ Vaughan, T.J.²⁰ Albert, V.R.²¹ more..

6
- 33646827589
- Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood b-lymphocyte populations in cynomolgus monkeys: Pharmacokinetic, pharmacodynamic, and toxicologic effects
- DOI 10.1093/toxsci/kfj148
- Halpern, W. G. et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol. Sci. 91, 586-599 (2006). (Pubitemid 43827311)
- (2006) Toxicological Sciences , vol.91 , Issue.2 , pp. 586-599
- Halpern, W.G.¹ Lappin, P.² Zanardi, T.³ Cai, W.⁴ Corcoran, M.⁵ Zhong, J.⁶ Baker, K.P.⁷

7
- 79955626131
- US Food and Drug Administration FDA website [online]
- US Food and Drug Administration. FDA labelling information - Benlysta. FDA website [online], http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 125370s0000lbl.pdf (2011).
- (2011) FDA Labelling Information - Benlysta

8
- 69749120918
- A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
- Wallace, D. J. et al. A Phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
- (2009) Arthritis Rheum. , vol.61 , pp. 1168-1178
- Wallace, D.J.¹

9
- 79955599423
- 28 Mar
- Yee, M. et al. RBC Capital Markets Equity Research (28 Mar 2011).
- (2011) RBC Capital Markets Equity Research
- Yee, M.¹

10
- 79955634366
- Credit Suisse Equity Research, 28 Mar
- Mehroti, R. et al. Human Genome Sciences (Credit Suisse Equity Research, 28 Mar 2011).
- (2011) Human Genome Sciences
- Mehroti, R.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.